• Explore /
  • Poster
  • / CONTACT-03: Randomized, open-label phase III study of atezolizumab plus cabozantinib versus cabozantinib monotherapy following progression on/after immune checkpoint inhibitor (ICI) treatment in patients with advanced/metastatic renal cell carcinoma.

CONTACT-03: Randomized, open-label phase III study of atezolizumab plus cabozantinib versus cabozantinib monotherapy following progression on/after immune checkpoint inhibitor (ICI) treatment in patients with advanced/metastatic renal cell carcinoma.

Abstract Video & Slides Poster

Authors

Sumanta Pal

Sumanta K. Pal

Department of Medical Oncology & Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA

Sumanta K. Pal , Laurence Albiges , Cristina Suarez Rodriguez , Bo Liu , Jennifer Doss , Sudha Khurana , Christian Scheffold , Martin H Voss , Toni K. Choueiri

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session: Renal Cell Cancer

Track

Renal Cell Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04338269

Citation

J Clin Oncol 39, 2021 (suppl 6; abstr TPS370)

DOI

10.1200/JCO.2021.39.6_suppl.TPS370

Abstract #

TPS370

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Andre Rashad Kydd

First Author: Deepak Kilari

First Author: Hung-Yang Kuo

First Author: Deepak Kilari